TScan Therapeutics to Participate in the Chardan 5th Annual Genetic Medicines Conference
TScan Therapeutics, focusing on T-cell receptor therapies for cancer, will have CEO David Southwell join a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Conference on October 5, 2021, at 2:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
TScan Therapeutics, focusing on T-cell receptor therapies for cancer, will have CEO David Southwell join a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Conference on October 5, 2021, at 2:00 p.m. ET. The chat will be accessible via live webcast on the company's website, with an archived replay available afterward. TScan is developing innovative treatments, including TSC-100 and TSC-101, targeting hematologic malignancies and various solid tumors.
Details
News Market Reaction – TCRX
The recorded move for TCRX in the trading session of this news was +4.44%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Chardan 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:00 p.m. ET.
A live webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website following the event.
About TScan Therapeutics, Inc.
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Contacts
Media Contact:
David Rosen
Argot Partners
212-600-1902
david.rosen@argotpartners.com
Investor Contact:
Sherri Spear
Argot Partners
212-600-1902
sherri@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.